Market access and value-based pricing of digital health applications in Germany

Gensorowsky D, Witte J, Batram M, Greiner W (2022)
Cost Effectiveness and Resource Allocation 20(1): 25.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Abstract / Bemerkung
**Abstract**
In December 2019, the Digital Health Care Act (“Digitale-Versorgung-Gesetz”) introduced a general entitlement to the provision and reimbursement of digital health applications (DiGA) for insured persons in the German statutory health insurance. As establishing a new digital service area within the solidarity-based insurance system implies several administrative and regulatory challenges, this paper aims to describe the legal framework for DiGA market access and pricing as well as the status quo of the DiGA market. Furthermore, we provide a basic approach to deriving value-based DiGA prices. To become eligible for reimbursement, the Federal Institute for Drugs and Medical Devices evaluates the compliance of a DiGA with general requirements (e.g., safety and data protection) and its positive healthcare effects (i.e., medical benefit or improvements of care structure and processes) in a fast-track process. Manufacturers may provide evidence for the benefits of their DiGA either directly with the application for the fast-track process or generate it during a trial phase that includes temporary reimbursement. After one year of \]reimbursement, the freely-set manufacturer price is replaced by a price negotiated between the National Association of Statutory Health Insurance Funds and the manufacturer. By February 2022, 30 DiGA had successfully completed the fast-track process. 73% make use of the trial phase and have not yet proven their benefit. Given this dynamic growth of the DiGA market and the low minimum evidence standards, fair pricing remains the central point of contention. The regulatory framework makes the patient-relevant benefits of a DiGA a pricing criterion to be considered in particular. Yet, it does not indicate how the benefits of a DiGA should be translated into a reasonable price. Our evidence-based approach to value-based DiGA pricing approximates the SHI’s willingness to pay by the average cost-effectiveness of one or more established therapy in a field of indication and furthermore considers the positive healthcare effects of a DiGA. The proposed approach can be fitted into DiGA pricing processes under the given regulatory framework and can provide objective guidance for price negotiations. However, it is only one piece of the pricing puzzle, and numerous methodological and procedural issues related to DiGA pricing are still open. Thus, it remains to be seen to what extent DiGA prices will follow the premise of value-based pricing.
Erscheinungsjahr
2022
Zeitschriftentitel
Cost Effectiveness and Resource Allocation
Band
20
Ausgabe
1
Art.-Nr.
25
eISSN
1478-7547
Page URI
https://pub.uni-bielefeld.de/record/2963863

Zitieren

Gensorowsky D, Witte J, Batram M, Greiner W. Market access and value-based pricing of digital health applications in Germany. Cost Effectiveness and Resource Allocation. 2022;20(1): 25.
Gensorowsky, D., Witte, J., Batram, M., & Greiner, W. (2022). Market access and value-based pricing of digital health applications in Germany. Cost Effectiveness and Resource Allocation, 20(1), 25. https://doi.org/10.1186/s12962-022-00359-y
Gensorowsky, D., Witte, J., Batram, M., and Greiner, W. (2022). Market access and value-based pricing of digital health applications in Germany. Cost Effectiveness and Resource Allocation 20:25.
Gensorowsky, D., et al., 2022. Market access and value-based pricing of digital health applications in Germany. Cost Effectiveness and Resource Allocation, 20(1): 25.
D. Gensorowsky, et al., “Market access and value-based pricing of digital health applications in Germany”, Cost Effectiveness and Resource Allocation, vol. 20, 2022, : 25.
Gensorowsky, D., Witte, J., Batram, M., Greiner, W.: Market access and value-based pricing of digital health applications in Germany. Cost Effectiveness and Resource Allocation. 20, : 25 (2022).
Gensorowsky, Daniel, Witte, Julian, Batram, Manuel, and Greiner, Wolfgang. “Market access and value-based pricing of digital health applications in Germany”. Cost Effectiveness and Resource Allocation 20.1 (2022): 25.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 35698135
PubMed | Europe PMC

Suchen in

Google Scholar